Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant

被引：10
|
作者：
Kovalenko, Angelina O. [1 ]
Ryabchevskaya, Ekaterina M. [1 ]
Evtushenko, Ekaterina A. [1 ]
Manukhova, Tatiana I. [1 ]
Kondakova, Olga A. [1 ]
Ivanov, Peter A. [1 ]
Arkhipenko, Marina V. [1 ]
Gushchin, Vladimir A. [1 ,2 ]
Nikitin, Nikolai A. [1 ]
Karpova, Olga V. [1 ]
机构：
[1] Lomonosov Moscow State Univ, Fac Biol, Dept Virol, Moscow, Russia
[2] Minist Hlth Russian Federat, NF Gamaleya Natl Res Ctr Epidemiol & Microbiol, Moscow, Russia
来源：
FRONTIERS IN MICROBIOLOGY | 2022年 / 13卷
基金：
俄罗斯基础研究基金会;
关键词：
coronaviruses; vaccine candidate; plant virus; adjuvant; tobacco mosaic virus; structurally modified plant virus; RECEPTOR-BINDING DOMAIN; TOBACCO-MOSAIC-VIRUS; SARS-COV-2; SPIKE; SPHERICAL-PARTICLES; SARS-COV; PROTEIN; MUTATIONS; INFECTION; EPITOPES; VIRIONS;
D O I：
10.3389/fmicb.2022.845316
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
A recombinant vaccine candidate has been developed based on the major coronaviruses' antigen (S protein) fragments and a novel adjuvant-spherical particles (SPs) formed during tobacco mosaic virus thermal remodeling. The receptor-binding domain and the highly conserved antigenic fragments of the S2 protein subunit were chosen for the design of recombinant coronavirus antigens. The set of three antigens (Co1, CoF, and PE) was developed and used to create a vaccine candidate composed of antigens and SPs (SPs + 3AG). Recognition of SPs + 3AG compositions by commercially available antibodies against spike proteins of SARS-CoV and SARS-CoV-2 was confirmed. The immunogenicity testing of these compositions in a mouse model showed that SPs improved immune response to the CoF and PE antigens. Total IgG titers against both proteins were 9-16 times higher than those to SPs. Neutralizing activity against SARS-CoV-2 in serum samples collected from hamsters immunized with the SPs + 3AG was demonstrated.
引用
收藏
页数：15
相关论文
共 50 条
  • [31] Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19
    Tong, Jiao
    Zhu, Chenxi
    Lai, Hanyu
    Feng, Chunchao
    Zhou, Dapeng
    VACCINES, 2021, 9 (03)
  • [32] Engineering a dual vaccine against COVID-19 and tuberculosis
    Guthrie, Carlyn Monet
    Tan, Xuejuan
    Meeker, Amber Cherry
    Self, Ashton Elisabeth
    Liu, Lin
    Cheng, Yong
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
  • [33] RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
    Liu, Zezhong
    Xu, Wei
    Xia, Shuai
    Gu, Chenjian
    Wang, Xinling
    Wang, Qian
    Zhou, Jie
    Wu, Yanling
    Cai, Xia
    Qu, Di
    Ying, Tianlei
    Xie, Youhua
    Lu, Lu
    Yuan, Zhenghong
    Jiang, Shibo
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [34] Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity
    Ghaemi, Amir
    Roshani Asl, Parisa
    Zargaran, Hedieh
    Ahmadi, Delaram
    Hashimi, Asim Ali
    Abdolalipour, Elahe
    Bathaeian, Sahar
    Miri, Seyed Mohammad
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [35] Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine
    Hu, Xing
    Xian, Mao-Ying
    Wang, Xi-Feng
    Zou, Guo-Qing
    Luo, Rui
    Peng, Hao
    Liu, Zheng
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (12): : 1647 - 1655
  • [36] Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection
    Yilmaz, Ismail Cem
    Ipekoglu, Emre Mert
    Bulbul, Artun
    Turay, Nilsu
    Yildirim, Muzaffer
    Evcili, Irem
    Yilmaz, Naz Surucu
    Guvencli, Nese
    Aydin, Yagmur
    Gungor, Bilgi
    Saraydar, Berfu
    Bartan, Asli Gulce
    Ibibik, Bilgehan
    Bildik, Tugce
    Baydemir, Ilayda
    Sanli, Hatice Asena
    Kayaoglu, Basak
    Ceylan, Yasemin
    Yildirim, Tugce
    Abras, Irem
    Ayanoglu, Ihsan Cihan
    Cam, Sefa Burak
    Dede, Eda Ciftci
    Gizer, Merve
    Erganis, Osman
    Sarac, Fahriye
    Uzar, Serdar
    Enul, Hakan
    Adiay, Cumhur
    Aykut, Gamze
    Polat, Hivda
    Yildirim, Ismail Selim
    Tekin, Saban
    Korukluoglu, Gulay
    Zeytin, Hasan Ersin
    Korkusuz, Petek
    Gursel, Ihsan
    Gursel, Mayda
    ALLERGY, 2022, 77 (01) : 258 - 270
  • [37] PdPANA: phagemid display as peptide array for neutralizing antibodies, an engineered in silico vaccine candidate against COVID-19
    Uzcategui, Javier
    Mullah, Khaleel
    de Virgini, Daniel Buvat
    Mendoza, Andres
    Urdaneta, Rafael
    Naranjo, Alejandra
    FRONTIERS IN SYSTEMS BIOLOGY, 2024, 4
  • [38] COVID-19: An update on vaccine development
    Tripathi, Deepak
    Yi, Guohua
    Vankayalapati, Ramakrishna
    INDIAN JOURNAL OF RHEUMATOLOGY, 2020, 15 (02) : 70 - 72
  • [39] COVID-19 Variants and Vaccine Development
    Zhao, Ziyao
    Bashiri, Sahra
    Ziora, Zyta M.
    Toth, Istvan
    Skwarczynski, Mariusz
    VIRUSES-BASEL, 2024, 16 (05):
  • [40] Assessment of a Structurally Modified Alternanthera Mosaic Plant Virus as a Delivery System for Sarcoma Cells
    Fayzullina, Daria
    Manukhova, Tatiana
    Evtushenko, Ekaterina
    Tsibulnikov, Sergey
    Kirgizov, Kirill
    Ulasov, Ilya
    Nikitin, Nikolai
    Karpova, Olga
    VIRUSES-BASEL, 2024, 16 (10):
12345